Drug General Information (ID: DDIDM3SXUZ)
Drug Name			Pegfilgrastim		Drug Info		Belantamab mafodotin		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Immunomodulatory Agents				Antineoplastics

Mechanism of Pegfilgrastim-Belantamab mafodotin Interaction (Severity Level: Moderate)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Pegfilgrastim				Belantamab mafodotin
Mechanism		Hematopoietic growth factors				Reduce therapeutic efficacy of hematopoietic growth factors
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Pegfilgrastim when combined with Belantamab mafodotin

Recommended Action
Management		Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.

References
1	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
2	Product Information. Neulasta (pegfilgrastim). Amgen, Thousand Oaks, CA.